Pharmaceutical

Defender’s plans for motion sickness nasal gel stop with FDA rejection

The NASA and US Navy-propelled company remains confident, with Defender CEO Barry Feinberg saying a meeting with the FDA has been requested.

Jan 31, 2024 - 18:00
Defender’s plans for motion sickness nasal gel stop with FDA rejection
The NASA and US Navy-propelled company remains confident, with Defender CEO Barry Feinberg saying a meeting with the FDA has been requested.
Read the original article

Tags:

Previous Article

Out with the old, in with the new: Decoding biosimilar access with VPAG 

Next Article

Biogen bids farewell to Aduhelm after tumultuous journey in Alzheimer’s

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ginkgo buys StrideBio’s AAV discovery and engineering platform assets

Ginkgo buys StrideBio’s AAV discovery and engineering p...

Apr 6, 2023

NorthSea Therapeutics bags FDA rare paediatric disease tag for NASH drug

NorthSea Therapeutics bags FDA rare paediatric disease ...

Oct 17, 2023

DF-003 by Drug Farm for Chronic Kidney Disease (Chronic...

Oct 29, 2023